Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.42 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27977023 | 0.88 | GAA (0.49) | SYKHDAC4HDAC1KDM4EMAP4K4 | |
| SCHEMBL846497 | 0.87 | CNR2 (0.47) | SYKHDAC4HDAC1KDM4EMAP4K4 | |
| SCHEMBL12101564 | 0.86 | HDAC4 (0.45) | SYKHDAC4HDAC1KDM4EMAP4K4 | |
| SCHEMBL4071391 | 0.86 | MALT1 (0.55) | HDAC4HDAC1KDM4EMAP4K4HDAC3 | |
| SCHEMBL6312640 | 0.85 | ALDH1A1 (0.53) | HDAC4HDAC1KDM4EMAP4K4HDAC3 | |
| SCHEMBL240482 | 0.84 | TRPV1 (0.61) | HDAC4HDAC1KDM4EHDAC3HDAC7 | |
| SCHEMBL29659720 | 0.81 | MALT1 (0.49) | SYKHDAC4HDAC1MAP4K4MAPKAPK2 | |
| SCHEMBL22926876 | 0.81 | MALT1 (0.49) | SYKHDAC4HDAC1MAP4K4MAPKAPK2 | |
| SCHEMBL23158879 | 0.80 | KAT6A (0.50) | SYKMAP4K4TRPV1TOP2ATOP2B | |
| SCHEMBL24096789 | 0.80 | SYK (0.45) | SYKHDAC4HDAC1MAP4K4HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755976-B1 | 6-SUBSTITUTED 3-(QUINOLIN-6-YLTHIO)-[1,2,4]TRIAZOLO[4,3-A]PYRIDINES AS C-MET TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-07-18 | — | — | EP | disclosed |
| EP-2755976-B1 | 6-SUBSTITUTED 3-(QUINOLIN-6-YLTHIO)-[1,2,4]TRIAZOLO[4,3-A]PYRIDINES AS C-MET TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-9474762-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474762-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20150250799-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2015-09-10 | — | — | US | disclosed |
| US-20150250799-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2015-09-10 | — | — | US | disclosed |
| US-9062045-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2015-06-23 | — | — | US | disclosed |
| US-9062045-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2015-06-23 | — | — | US | disclosed |
| EP-2755976-A1 | 6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4]TRIAZOLO [4, 3 -A]PYRADINES AS TYROSINE KINASE | Novartis AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-20130245002-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | disclosed |
| US-20130245002-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | disclosed |
| WO-2013038362-A1 | 6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4] TRIAZOLO [4, 3 -A] PYRADINES AS TYROSINE KINASE | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013038362-A1 | 6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4] TRIAZOLO [4, 3 -A] PYRADINES AS TYROSINE KINASE | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250799-A1 | Triazolopyridine Compounds | FLT3, RET, MET | SYK 48/4885HDAC4 3678/4885HDAC1 3781/4885 |
| US-20130245002-A1 | Triazolopyridine Compounds | FLT3, RET, MET | SYK 48/4885HDAC4 3678/4885HDAC1 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.